Fairvalue-Calculator Fairvalue-Calculator
EN DE

Lixte Biotechnology Holdings (LIXT) Fair Value & Analysis

Healthcare · US · Market cap $132M

Price$7.30
Fair Value$2.50
Upside-65.8%
Quality80/100
Evidence: Low Range $1.88 – $3.13

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Lixte Biotechnology Holdings (LIXT) currently trades at $7.30, while our model-based Fair Value estimate is $2.50 — implying the stock looks roughly 65.8% overvalued today. We read business quality at 80/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical and proton cancer therapy company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Boca Raton, Florida.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Lixte Biotechnology Holdings (LIXT) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $2.50 versus a price of $7.30 — about −66% (overvalued). Model-based estimate, not financial advice.
What is the fair value of LIXT?
Our 21-model fair value for Lixte Biotechnology Holdings is $2.50 (as of Jun 24, 2026), built from audited fundamentals. The current price is $7.30.
What is the quality score of LIXT?
Lixte Biotechnology Holdings has a Quality Score of 80/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.